long intergenic non-protein coding RNA 2610Genealiases: []
Q-omics provides the consensus-scored LINC02610 profile across patient tissues and cancer cell-line models. LINC02610 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02610 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LINC02610 RNA expression shows 11,311 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where LINC02610 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02610 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02610 survival associations across molecular data types. LINC02610 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02610 RNA expression–survival associations across cancer types. High LINC02610 expression shows favorable associations in HNSC, BLCA, UCS, UVM, LUAD and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02610 RNA expression.
This table summarizes LINC02610 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02610. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02610 shows lower tumor expression in KIRC, KIRP, KICH, BRCA, COAD and UCEC. The KIRC box plot shows higher LINC02610 RNA expression in normal versus tumor tissue (log2 FC = −0.492, t-test p < 0.001).
This table shows molecular features associated with LINC02610 in patient tissues and cancer cell lines. In patient samples, LINC02610 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
